Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 289

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry

Open access
López-Sendón, José, Álvarez-Ortega, Carlos, Zamora Auñon, Pilar, Buño Soto, Antonio, Lyon, Alexander R, Farmakis, Dimitrios, Cardinale, Daniela, Canales Albendea, Miguel, Feliu Batlle, Jaime, Rodríguez Rodríguez, Isabel, Rodríguez Fraga, Olaia, Albaladejo, Ainara, Mediavilla, Guiomar, González-Juanatey, Jose Ramón, Martínez Monzonis, Amparo, Gómez Prieto, Pilar, González-Costello, José, Serrano Antolín, José María, Cadenas Chamorro, Rosalía, López Fernández, Teresa·2020·European Heart Journal

Abstract

Aim: Cardiotoxicity (CTox) is a major side effect of cancer therapies, but uniform diagnostic criteria to guide clinical and research practices are lacking. Methods and results: We prospectively studied 865 patients, aged 54.7 ± 13.9; 16.3% men, scheduled for anticancer therapy related with moderate/high CTox risk. Four groups of progressive myocardial damage/dysfunction were considered according to current guidelines: normal, normal biomarkers (high-sensitivity troponin T and N-terminal natriuretic pro-peptide), and left ventricular (LV) function; mild, abnormal biomarkers, and/or LV dysfunction (LVD) maintaining an LV ejection fraction (LVEF) ≥50%; moderate, LVD with LVEF 40–49%; and severe, LVD with LVEF ≤40% or symptomatic heart failure. Cardiotoxicity was defined as new or worsening of myocardial damage/ventricular function from baseline during follow-up. Patients were followed for a median of 24 months. Cardiotoxicity was identified in 37.5% patients during follow-up [95% confidence interval (CI) 34.22–40.8%], 31.6% with mild, 2.8% moderate, and 3.1% with severe myocardial damage/dysfunction. The mortality rate in the severe CTox group was 22.9 deaths per 100 patients-year vs. 2.3 deaths per 100 patients-year in the rest of groups, hazard ratio of 10.2 (95% CI 5.5–19.2) (P < 0.001). Conclusions: The majority of patients present objective data of myocardial injury/dysfunction during or after cancer therapy. Nevertheless, severe CTox, with a strong prognostic relationship, was comparatively rare. This should be reflected in protocols for clinical and research practices.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehaa006

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 44 references

Cited by

See all 289

Metadata

Authors
López-Sendón, J., Álvarez-Ortega, C., Zamora Auñon, P., Buño Soto, A., Lyon, A. R., Farmakis, D., Cardinale, D., Canales Albendea, M., Feliu Batlle, J., Rodríguez Rodríguez, I., Rodríguez Fraga, O., Albaladejo, A., Mediavilla, G., González-Juanatey, J. R., Martínez Monzonis, A., Gómez Prieto, P., González-Costello, J., Serrano Antolín, J. M., Cadenas Chamorro, R., & López Fernández, T.
Venue
European Heart Journal
Published
2020-02-04
Volume
41
Issue
18
Pages
1720-1729
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W3005517924
Cited by
289
References
44
FWCI
21.09
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. https://app.cochat.ai/papers/10.1093/eurheartj/ehaa006
The paper
López-Sendón, J., Álvarez-Ortega, C., Zamora Auñon, P., Buño Soto, A., Lyon, A. R., Farmakis, D., Cardinale, D., Canales Albendea, M., Feliu Batlle, J., Rodríguez Rodríguez, I., Rodríguez Fraga, O., Albaladejo, A., Mediavilla, G., González-Juanatey, J. R., Martínez Monzonis, A., Gómez Prieto, P., González-Costello, J., Serrano Antolín, J. M., Cadenas Chamorro, R., & López Fernández, T. (2020). Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. European Heart Journal. https://doi.org/10.1093/eurheartj/ehaa006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.